15 completed, 8 active not recruiting, 5 terminated, 2 recruiting. 17 Phase 2, 10 Phase 1, 10 Phase 3, 2 Early Phase 1, 1 Not applicable.
Follow Ovarian Serous Adenocarcinoma: new trials by email Literature Review of Ovarian Serous Adenocarcinoma trials Research Report on Ovarian Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study ICI-HIPET - HIPEC, Ovarian Serous Adenocarcinoma | Phase 2 | Not yet recruiting | Jing Li | 30 | 2025-08-01 | 2025-07-16 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Oregovomab, Paclitaxel, Carboplatin - Ovarian Neoplasm Epithelial, Ovarian Cancer | Phase 2 | Active not recruiting | CanariaBio Inc. | 88 | 2023-02-07 | 2026-10-23 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer Carboplatin, Cisplatin, Cytoreductive Surgery - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Early Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2022-06-13 | 2026-08-17 |
| A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors ZB131 - Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma | Phase 1 / Phase 2 | Completed | ZielBio, Inc. | 35 | 2022-01-14 | 2024-01-29 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Completed | Imperial College London | 134 | 2018-09-21 | 2024-09-20 |
| Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Durvalumab, Laboratory Biomarker Analysis, Olaparib - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2017-06-29 | 2024-11-19 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2016-09-01 | 2021-10-06 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Hsp90 Inhibitor AT13387, Laboratory Biomarker Analysis, Pharmacological Study - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-03-01 | 2016-07-26 | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers Plerixafor - Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma | Phase 1 | Completed | CCTU- Cancer Theme | 26 | 2015-06-01 | 2019-07-23 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
Showing 20 of 34. Sign in to see all of them.
Fallopian Tube Neoplasms (25) · Ovarian Neoplasms (25) · Brenner Tumor (13) · Pancreatic Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Carcinoma (2) · Carcinoma, Ovarian Epithelial (2) · Colorectal Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Endometrioid (1) · Carcinoma, Non-Small-Cell Lung (1)
Neoplasms (32) · Adnexal Diseases (31) · Female Urogenital Diseases (31) · Female Urogenital Diseases and Pregnancy Complications (31) · Genital Diseases (31) · Genital Diseases, Female (31) · Genital Neoplasms, Female (31) · Urogenital Diseases (31) · Urogenital Neoplasms (31) · Neoplasms by Site (30) · Endocrine System Diseases (29) · Gonadal Disorders (29) · Ovarian Diseases (28) · Endocrine Gland Neoplasms (25) · Fallopian Tube Diseases (25)
Paclitaxel (16) · Taxes (14) · Disulfides (12) · Immunoglobulin G (12) · Bevacizumab (11) · Carboplatin (10) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Cisplatin (3) · Doxorubicin (3) · Magnetic Resonance Spectroscopy (3) · Platinum (3) · Specimen Handling (3) · Topotecan (3) · liposomal doxorubicin (3) · olaparib (3)
National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (4) · Mayo Clinic (3) · Roswell Park Cancer Institute (3) · CanariaBio Inc. (2) · GOG Foundation (2) · CCTU- Cancer Theme (1) · Elucida Oncology (1) · Gynecologic Oncology Group (1) · Imperial College London (1) · Jing Li (1) · Ohio State University Comprehensive Cancer Center (1) · PX Biosolutions (1) · TCR2 Therapeutics (1) · University of Washington (1)
United States (28) · Canada (5) · South Korea (5) · Japan (3) · United Kingdom (3) · India (2) · Italy (2) · Mexico (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Chile (1) · China (1) · Czechia (1)
Emese Zsiros (3) · Anil K. Sood, MD (1) · Anil Sood (1) · Bradley J Monk (1) · David Alberts (1) · David M Gershenson (1) · Don Dizon (1) · Evanthia Galanis, M.D. (1) · Evanthia Galanis, MD (1) · Floor Backes, MD (1) · Jada Srinivasa Rao, PhD (1) · Joan L Walker (1) · John K Chan (1) · Jonathan Krell (1) · Jose A Rauh-Hain (1)
PMID 37185961, PMID 21941283, PMID 22204724, PMID 23219660, PMID 23810467, PMID 25218906, PMID 26487588, PMID 26933849, PMID 27394382, PMID 28341300, PMID 28438473, PMID 29550184, PMID 30309721, PMID 31002578, PMID 31216226, PMID 31708167, PMID 31722153, PMID 33211063, PMID 33610319, PMID 34986897, PMID 35123694, PMID 35144591, PMID 35382842, PMID 35759733, PMID 36252167, PMID 36608382, PMID 39361946, PMID 39570589, PMID 39638782
U10CA180868 (10), U10CA027469 (8), P30CA006516 (2), UM1CA186709 (2), 2014 (1), N01CM00071 (1), P30CA016672 (1), P50CA083639 (1), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1), R01CA267690 (1), R21CA215662 (1), U01CA062490 (1), U10CA101165 (1)